Emergent BioSolutions (EBS) Tops Q2 EPS by 26c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.46 -0.82%
EPS Growth %: -31.3%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
DTGI, OCCI, MAYS, More
EPS Growth %: -31.3%
Financial Fact:
Income (loss) from operations: 35.48M
Today's EPS Names:
DTGI, OCCI, MAYS, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.16, $0.26 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $140.9 million versus the consensus estimate of $174 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
- Jones Trading Starts Alterity Therapeutics (ATHE) at Buy
- Italgas SpA (IG:IM) PT Raised to EUR11.20 at RBC Capital
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
